ClinicalTrials.gov
ClinicalTrials.gov Menu

Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome (IRIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01557803
Recruitment Status : Completed
First Posted : March 20, 2012
Last Update Posted : January 14, 2015
Sponsor:
Collaborators:
University Hospital Tuebingen
Albert Schweitzer Hospital
Information provided by (Responsible Party):
S. Janssen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this project is to determine clinical and biological predictors of Immune Reconstitution Inflammatory Syndrome (IRIS) occurrence in HIV infected patients who are started on antiretroviral therapy (ART), and to obtain more insight into the pathogenesis of this syndrome. The investigators will prospectively study HIV infected patients in Sub Saharan Africa who will be initiated on ART and are at risk to develop IRIS in all its different appearances. In these patients, the investigators will assess the value of clinical features and plasma biomarkers to predict IRIS, and the investigators will obtain insight into which inflammatory pathways become activated during IRIS. This project will provide novel knowledge about this clinically highly relevant healthcare problem in a resource poor setting, namely in Lambaréné, Gabon, in the Central African rainforest belt. In Gabon little research has been done in the field of HIV. The epidemiological pattern of IRIS in Gabon will be described. Promising putative plasma biomarkers will be validated for their use in daily practice.

Condition or disease
Immune Reconstitution Inflammatory Syndrome Opportunistic Infections

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 107 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome in Lambaréné, Gabon
Study Start Date : January 2012
Actual Primary Completion Date : February 2014
Actual Study Completion Date : January 2015
Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Starting ART
Adult patients starting anti retroviral therapy for the first time


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. IRIS [ Time Frame: 12 months ]
    Development of immune reconstitution inflammatory syndrome


Secondary Outcome Measures :
  1. Time to IRIS [ Time Frame: 12 months ]
    Time to development of immune reconstitution inflammatory syndrome


Biospecimen Retention:   Samples Without DNA
Plasma, Paxgene RNA tubes and urine

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult HIV patients starting anti retroviral therapy for the first time
Criteria

Inclusion Criteria:

  • Age > 18 years
  • Informed consent
  • ART naive

Exclusion Criteria:

  • No informed consent
  • History of ART use
  • Pregnancy
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01557803


Locations
Gabon
Medical Research Unit - Albert Schweitzer Hospital
Lambaréné, Moyen Ogoué, Gabon, BP118
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
University Hospital Tuebingen
Albert Schweitzer Hospital
Investigators
Study Chair: MP Grobusch, MD, MSc Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: S. Janssen, MD, MSc, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT01557803     History of Changes
Obsolete Identifiers: NCT01549821
Other Study ID Numbers: MRU-HAS 006/2012
First Posted: March 20, 2012    Key Record Dates
Last Update Posted: January 14, 2015
Last Verified: January 2015

Keywords provided by S. Janssen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Immune reconstitution inflammatory syndrome
Biomarkers
HIV
ART
 predictive factors
epidemiological pattern
Gabon

Additional relevant MeSH terms:
Syndrome
Opportunistic Infections
Immune Reconstitution Inflammatory Syndrome
Disease
Pathologic Processes
 Infection
Virus Diseases
Parasitic Diseases
Immune System Diseases